Although these notions were obtained in the study of cell lines, our observations validate the clinical benefit of 6MP dose adjustment for BCP‐ALL and T‐ALL patients who carry the NUDT15 variant allele by reducing myelosuppression without compromising anti‐leukemic efficacy. The gene discussed is NUDT15; the disease is acute lymphoblastic leukemia.